Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

    Interim Management Statement - 3 months to 31 December 2013 (unaudited)    

Worldwide Healthcare Trust PLC invests in the global healthcare sector with the
objective of achieving a high level of capital growth. In order to achieve its 
investment objective, the Company invests worldwide in a diversified portfolio 
of shares in pharmaceutical and biotechnology companies and related securities 
in the healthcare sector. The Company uses gearing and derivative transactions 
                  to mitigate risk and also enhance returns.                   

During the 3 month period ended 31 December 2013 the Company's fully diluted
net asset value per share total return was 8.8%, in line with the Company's
share price total return; both outperformed the Company's benchmark, the MSCI
World Health Care Index measured in sterling terms on a total return basis,
which rose by 6.4% during the period. Overall, exposure to North America and
also to large capitalisation stocks was increased while holdings in Europe and
small capitalisation stocks were reduced. At the stock level, the percentage
holding in Gilead Sciences rose and a position in Regeneron Pharmaceuticals was
established while those in Roche and Merck fell.

During the three-month period 211,349 new shares were issued, as a result of
holders of subscription shares exercising their subscription rights, raising £
1.5m of additional funds for the Company.

Since the period end, to the date of this report, 192,377 new shares were
allotted, as a result of holders of subscription shares exercising their
subscription rights, raising £1.3m of additional funds for the Company. As at
14 February 2014 there are 46,292,111 shares in issue. There are also 1,860,969
subscription shares in issue.

In the period from 31 December 2013 to 12 February 2014, the Company's fully
diluted net asset value per share total return was 7.5%, compared to a return
of 3.4% from the Company's benchmark. The share price total return was 4.6%.

A first interim dividend of 7.0p per share, for the year to 31 March 2014, was
paid on 10 January 2014 to shareholders on the register of members on 6
December 2013. The associated ex-dividend date was 4 December 2013.

Trust Characteristics

                                   31 December 2013      30 September 2013     
                                                                               
Number of holdings                        62                       57          
                                                                               
Net assets (£m)                         593.6                    548.4         
                                                                               
Indicative yield                         1.3%                     1.4%         
                                                                               
Gearing (AIC basis)                      11%                      12%          
                                                                               
Share price (p)                        1239.00                  1145.00        
                                                                               
NAV (p) -undiluted (ex                 1284 .59                 1187.54        
income)                                                                        
                                                                               
NAV (p) diluted: sub shares            1259.62                  1164.56        
(ex income)                                                                    
                                                                               
(Discount)/premium                      (3.5%)                   (3.6%)        
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted -             (1.6%)                   (1.7%)        
sub shares)                                                                    
                                                                               
Subscription share price (p)            521.00                   444.00        

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                      % of            
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2013      at 30 September 2013    
                                                                               
Roche                                 7.2                       7.6            
                                                                               
Gilead Sciences                       5.3                       4.9            
                                                                               
Regeneron Pharmaceuticals             3.8                        -             
                                                                               
HCA                                   3.6                       2.7            
                                                                               
Incyte                                3.4                       3.1            
                                                                               
Merck & Co                            3.4                       4.5            
                                                                               
Bristol-Myers Squibb                  3.4                       3.2            
                                                                               
Mylan                                 3.4                       3.3            
                                                                               
Amgen                                 3.2                       3.5            
                                                                               
Biogen Idec                           2.8                       3.9            
                                                                               
Total                                39.5                      36.7            

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2013       at 30 September 2013   
                                                                               
Large capitalisation                 74.5                       68.7           
                                                                               
Small capitalisation                 25.5                       31.3           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                             at 31 December 2013        at 30 September 2013   
                                                                               
North America                        69.3                       67.2           
                                                                               
Europe                               11.5                       13.7           
                                                                               
Asia                                 8.7                        8.0            
                                                                               
Emerging Markets                     10.5                       11.1           
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2013

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +8.8%           +47.1%          +88.4%          +141.6%        
                                                                               
NAV Fully       +8.8%           +44.6%          +77.4%          +123.1%        
diluted                                                                        
                                                                               
Benchmark*      +6.4%           +33.6%          +66.1%          +88.3%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Reuters and Bloomberg

*Benchmark - With effect from 1 October 2010, the performance of the Company is
measured against the MSCI World Health Care Index on a total return, sterling
adjusted basis. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index measured in sterling
terms on a total return basis. Historic data, therefore, consists of a blended
figure containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the Company's website www.worldwidewh.com and
on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares

SEDOL- 0338530

ISIN - GB0003385308

Bloomberg - WWH LN

EPIC - WWH

Subscription Shares

SEDOL - B3VMCB0

ISIN - GB00B3VMCB07

Bloomberg - WWHS LN

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

14 February 2014